June 5, 2017 / 12:06 AM / 3 months ago

BRIEF-Prima Biomed says LAG-3IG demonstrates positive safety and efficacy qualities in breast cancer clinical trial

June 5 (Reuters) - Prima Biomed Ltd

* LAG-3Ig (IMP321) demonstrates positive safety and efficacy qualities in breast cancer clinical trial

* Data shows IMP321 in combination with chemotherapy leads to sustainable increase in antigen presenting cells, CD8 T cells and improved pre-dose TH1 status Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below